The European Medicines Agency is recommending approval of Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) – a rare and often fatal disease affecting neurons in the brain and spinal cord that control muscle movement. SMA is caused by mutations in the SMN1 gene that encodes for the survival motor neuron protein.
